Similar articles

• Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data.

  Trinh QD, Schrag D. Trinh QD, et al. JAMA Intern Med. 2014 Sep;174(9):1468-9. doi: 10.1001/jamainternmed.2014.1107. JAMA Intern Med. 2014. PMID: 25023522 No abstract available.
• Prostate cancer: is androgen-deprivation therapy chosen wisely?

  Villanueva MT. Villanueva MT. Nat Rev Clin Oncol. 2014 Sep;11(9):501. doi: 10.1038/nrclinonc.2014.130. Epub 2014 Jul 29. Nat Rev Clin Oncol. 2014. PMID: 25073003 No abstract available.
• Hormone-refractory prostate cancer: what have we learned?

  Wirth MP. Wirth MP. BJU Int. 2007 Jul;100 Suppl 2:56-9. doi: 10.1111/j.1464-410X.2007.06957.x. BJU Int. 2007. PMID: 17594362 Review. No abstract available.
• Prostate cancer: Say no to ADT for localized disease.

  Payton S. Payton S. Nat Rev Urol. 2014 Sep;11(9):487. doi: 10.1038/nrurol.2014.187. Epub 2014 Jul 29. Nat Rev Urol. 2014. PMID: 25069734 No abstract available.
• Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.

  Boudreaux KJ, Chang SS. Boudreaux KJ, et al. BJU Int. 2008 Mar;101(6):671-4. doi: 10.1111/j.1464-410X.2007.07336.x. Epub 2007 Dec 7. BJU Int. 2008. PMID: 18070172 Review. No abstract available.